Evidence map›Paper›PMID 26191134›Full record

ArticleInternational journal of clinical and experimental pathology2015

Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.

Patrick Vianna Garcia, Letícia Montanholi Apolinário, Petra Karla Böckelmann, Iseu da Silva Nunes, Nelson Duran, Wagner José Fávaro

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. OncoTheradJournal of cancer research and clinical oncology · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Patrick Vianna GarciaDepartment of Structural and Functional Biology, Laboratory of Urogenital Carcinogenesis and Immunotherapy, University of Campinas (UNICAMP) Campinas, SP, Brazil.
Letícia Montanholi ApolinárioDepartment of Structural and Functional Biology, Laboratory of Urogenital Carcinogenesis and Immunotherapy, University of Campinas (UNICAMP) Campinas, SP, Brazil.
Petra Karla BöckelmannDepartment of Structural and Functional Biology, Laboratory of Urogenital Carcinogenesis and Immunotherapy, University of Campinas (UNICAMP) Campinas, SP, Brazil.
Iseu da Silva NunesFarmabrasilis R&D Division, Campinas, SP, Brazil, Biol Chem Lab., University of Campinas (UNICAMP) Campinas, SP, Brazil.
Nelson DuranFarmabrasilis R&D Division, Campinas, SP, Brazil, Biol Chem Lab., University of Campinas (UNICAMP) Campinas, SP, Brazil ; Institute of Chemistry, Biol Chem Lab., University of Campinas (UNICAMP) Campinas, SP, Brazil ; Institute of Chemistry, NanoBioss, University of Campinas (UNICAMP) Campinas, SP, Brazil.
Wagner José FávaroDepartment of Structural and Functional Biology, Laboratory of Urogenital Carcinogenesis and Immunotherapy, University of Campinas (UNICAMP) Campinas, SP, Brazil ; Farmabrasilis R&D Division, Campinas, SP, Brazil, Biol Chem Lab., University of Campinas (UNICAMP) Campinas, SP, Brazil.
Universidade Estadual de Campinas (UNICAMP) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study describes the role of the ubiquitin ligase Siah-2 and corepressor N-CoR in controlling androgen receptor (AR) and estrogen receptors (ERα and ERβ) signaling in an appropriate animal model (Fischer 344 female rats) of non-muscle invasive bladder cancer (NMIBC), especially under conditions of anti-androgen therapy with flutamide. Furthermore, this study describes the mechanisms of a promising therapeutic alternative for NMIBC based on Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride (P-MAPA) intravesical immunotherapy combined with flutamide, involving the interaction among steroid hormone receptors, their regulators and Toll-like receptors (TLRs). Our results demonstrated that increased Siah-2 and AR protein levels and decreased N-CoR, cytochrome P450 (CYP450) and estrogen receptors levels played a critical role in the urothelial carcinogenesis, probably leading to escape of urothelial cancer cells from immune system attack. P-MAPA immunotherapy led to distinct activation of innate immune system TLRs 2 and 4-mediated, resulting in increase of interferon signaling pathway, which was more effective in recovering the immunosuppressive tumor immune microenvironment and in recovering the bladder histology features than BCG (Bacillus Calmette-Guerin) treatments. The AR blockade therapy was important in the modulating of downstream molecules of TLR2 and TLR4 signaling pathway, decreasing the inflammatory cytokines signaling and enhancing the interferon signaling pathway when associated with P-MAPA. Taken together, the data obtained suggest that interferon signaling pathway activation and targeting AR and Siah-2 signals by P-MAPA intravesical immunotherapy alone and/ or in combination with AR blockade may provide novel therapeutic approaches for NMIBC.

Indexed as

Administration, IntravesicalAndrogen AntagonistsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBlotting, WesternDisease Models, AnimalFemaleFlutamideImmunotherapyLinoleic AcidsNuclear Receptor CoactivatorsOrganophosphorus CompoundsRatsRats, Inbred F344Receptors, AndrogenUbiquitin-Protein LigasesAndrogen AntagonistsFlutamideLinoleic Acidsmagnesium ammonium phospholinoleate anhydrideNcoa6 protein, ratNuclear Receptor CoactivatorsOrganophosphorus CompoundsReceptors, AndrogenUbiquitin-Protein Ligasesandrogen receptorBladder cancerestrogen receptorflutamideimmunotherapyN-CoRP-MAPASiah2toll-like receptor

Identifiers

PMID26191134
PMCPMC4503006
OpenAlexW2415844411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.